Pulmonary Adenocarcinoma

Pulmonary adenocarcinoma is a malignant epithelial neoplasm arising from the bronchial, bronchiolar, or alveolar epithelium of the lung. It is the most common primary lung tumor in dogs and the second most common in cats, after bronchioloalveolar carcinoma. The tumor is characterized by glandular differentiation, which may manifest as acinar, papillary, solid, or mixed patterns. Pulmonary adenocarcinoma is typically a primary tumor, but it can also represent metastatic disease from other sites, particularly in cats. The disease is often asymptomatic in early stages, and clinical signs are usually nonspecific, such as chronic cough, dyspnea, and weight loss. The tumor has a high metastatic potential, with common sites including regional lymph nodes, pleura, and distant organs such as bone, brain, and liver. Early diagnosis and surgical resection offer the best chance for prolonged survival, but the prognosis remains guarded due to the high rate of metastasis.

The exact etiology of pulmonary adenocarcinoma is largely unknown, but several risk factors have been identified. In dogs, exposure to environmental carcinogens, such as secondhand tobacco smoke, has been associated with an increased risk of lung cancer, including adenocarcinoma. In cats, the development of pulmonary adenocarcinoma has been linked to exposure to environmental tobacco smoke and possibly to feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infections, although a direct causal relationship has not been established. Genetic mutations, such as activation of oncogenes (e.g., KRAS, EGFR) or inactivation of tumor suppressor genes (e.g., p53), are believed to play a role in tumorigenesis, but specific mutations have not been consistently identified in veterinary medicine. Chronic pulmonary inflammation, such as that caused by chronic bronchitis or pneumonia, may also predispose to neoplastic transformation, although this association is not well-documented. In addition, certain breeds, such as Boxers and Doberman Pinschers, appear to have a higher incidence, suggesting a genetic predisposition.

Pulmonary adenocarcinoma is the most common primary lung tumor in dogs, accounting for approximately 75% of all primary lung tumors. It is less common in cats, where it represents about 50% of primary lung tumors. The disease typically affects older animals, with a median age of 10-12 years in dogs and 12-14 years in cats. There is no strong sex predilection, although some studies suggest a slight female predominance in dogs. Brachycephalic breeds, such as Boxers and Bulldogs, may be at increased risk, as are large-breed dogs like Doberman Pinschers and German Shepherds. In cats, no specific breed predilection has been consistently identified. The incidence of pulmonary adenocarcinoma appears to be increasing, possibly due to improved diagnostic imaging and increased awareness, as well as environmental factors. No geographic or seasonal variation has been reported.

Pulmonary adenocarcinoma arises from the epithelial cells lining the airways or alveoli. The tumor typically grows as a solitary mass, most commonly in the caudal lung lobes, but can be multifocal. Histologically, the tumor exhibits glandular differentiation, with cells forming acini, tubules, or papillary structures. The tumor cells may produce mucin, and there is often a desmoplastic stromal reaction. The tumor invades local pulmonary parenchyma and can spread via the lymphatic and vascular systems. Metastasis to regional lymph nodes, particularly the tracheobronchial and mediastinal lymph nodes, is common. Hematogenous spread to distant organs, including the brain, bone, liver, and adrenal glands, occurs in advanced stages. The tumor can also invade the pleura, leading to pleural effusion, which is more common in cats. The pathophysiological consequences include respiratory compromise due to mass effect, airway obstruction, and pleural effusion. Paraneoplastic syndromes, such as hypertrophic osteopathy and hypercalcemia, may occur due to tumor secretion of growth factors or cytokines.

Several factors may predispose animals to the development of pulmonary adenocarcinoma. Age is a significant risk factor, with the disease occurring most commonly in older animals. Breed predisposition has been noted in dogs, with Boxers, Doberman Pinschers, and German Shepherds being overrepresented. Exposure to environmental carcinogens, particularly secondhand tobacco smoke, has been associated with an increased risk in both dogs and cats. In cats, living in households with smokers has been shown to increase the risk of lung cancer. Chronic pulmonary disease, such as chronic bronchitis or pulmonary fibrosis, may also predispose to neoplastic transformation, although the evidence is limited. Immunosuppression, whether due to viral infections (e.g., FeLV, FIV) or immunosuppressive therapy, may increase the risk of tumor development. Genetic factors, including inherited mutations in tumor suppressor genes or oncogenes, are likely involved but are not well-characterized in veterinary medicine.

Clinical signs of pulmonary adenocarcinoma are often insidious and may be absent in early stages. When present, the most common signs include chronic cough, which may be dry or productive, and exercise intolerance. Dyspnea or tachypnea may occur as the tumor grows or if pleural effusion develops. Hemoptysis is uncommon but can occur. Systemic signs such as weight loss, lethargy, anorexia, and fever may be present, especially in advanced disease. Paraneoplastic syndromes, such as hypertrophic osteopathy, may cause lameness and limb swelling. In cats, clinical signs may be more subtle, and respiratory signs may be less prominent; instead, weight loss and lethargy may be the primary complaints. Physical examination findings may include abnormal lung sounds (wheezes, crackles), dullness on thoracic percussion if pleural effusion is present, and, in cases of hypertrophic osteopathy, firm swelling of the distal limbs.

Differential diagnoses for pulmonary adenocarcinoma include other primary lung tumors, such as squamous cell carcinoma, bronchoalveolar carcinoma, and pulmonary lymphoma. Metastatic lung tumors from other primary sites (e.g., mammary gland, bone, melanoma) are also important to consider. Non-neoplastic conditions that can mimic pulmonary adenocarcinoma include granulomatous diseases (e.g., fungal pneumonia, tuberculosis), pulmonary abscesses, and benign pulmonary nodules (e.g., hamartomas). In cats, pulmonary adenocarcinoma must be differentiated from other causes of pleural effusion, such as feline infectious peritonitis (FIP), congestive heart failure, and lymphoma. Key distinguishing features include the presence of a solitary mass on imaging, cytological or histopathological evidence of glandular differentiation, and the absence of infectious agents. Advanced imaging, such as CT, and biopsy are often necessary to confirm the diagnosis.

The diagnostic workup for suspected pulmonary adenocarcinoma begins with a thorough history and physical examination. Thoracic radiographs are the initial imaging modality of choice and may reveal a solitary pulmonary mass, often in the caudal lung lobes. If a mass is identified, thoracic CT is recommended to better characterize the lesion, assess for lymph node involvement, and screen for pulmonary metastases. Fine-needle aspiration (FNA) of the mass, guided by ultrasound or CT, can provide cytological evidence of neoplasia, but histopathology is required for definitive diagnosis. Bronchoscopy with bronchoalveolar lavage (BAL) may be performed if the mass is centrally located, and biopsy samples can be obtained via forceps. In cases with pleural effusion, thoracocentesis and fluid analysis may reveal neoplastic cells. Staging for metastasis should include abdominal ultrasound and, if indicated, bone scintigraphy or MRI of the brain. Histopathological examination of the biopsy specimen, including immunohistochemistry (e.g., cytokeratin, thyroid transcription factor-1), can confirm the diagnosis and help differentiate from metastatic tumors.

Complete blood count (CBC) may reveal a mild leukocytosis due to inflammation or paraneoplastic neutrophilia. Anemia may be present in chronic disease. Serum biochemistry may show hypercalcemia in cases of paraneoplastic hypercalcemia, and liver enzyme elevations may indicate metastatic disease. Serum biomarkers such as C-reactive protein (CRP) may be elevated. In cats, testing for FeLV and FIV is recommended. Thoracocentesis fluid analysis, if pleural effusion is present, typically reveals a modified transudate or exudate with neoplastic cells, which may be arranged in acini or clusters. Cytological evaluation of FNA samples may show cohesive clusters of epithelial cells with anisocytosis, anisokaryosis, and prominent nucleoli. Histopathology is essential for grading the tumor and assessing mitotic index, which has prognostic significance.

Thoracic radiographs are the first-line imaging modality and typically show a solitary, well-circumscribed soft tissue mass, most commonly in the caudal lung lobes. The mass may be cavitated or have an irregular border. In cats, pleural effusion is a common finding, which may obscure the underlying mass. Thoracic CT is superior to radiography for detecting small masses, evaluating the extent of local invasion, and identifying mediastinal lymphadenopathy. CT also allows for accurate staging and surgical planning. Abdominal ultrasound is recommended to screen for metastatic disease in the liver, spleen, and adrenal glands. If neurological signs are present, MRI of the brain may be indicated to rule out brain metastases. Echocardiography is not typically indicated unless cardiac disease is suspected. In cases of hypertrophic osteopathy, radiographs of the limbs may show periosteal new bone formation.

Cytological examination of FNA samples from pulmonary adenocarcinoma often reveals clusters of epithelial cells with moderate to marked anisocytosis and anisokaryosis. The cells may have a cuboidal or columnar shape, and acinar or papillary arrangements may be seen. Nuclei are often large with prominent nucleoli, and the cytoplasm may contain mucin vacuoles. However, cytology alone is not definitive, as well-differentiated tumors may resemble normal bronchial epithelium. Histopathology is the gold standard for diagnosis. The tumor is characterized by invasive growth with glandular differentiation, which may be acinar, papillary, solid, or mixed. The mitotic index is variable and has prognostic significance. Immunohistochemistry can be used to differentiate primary pulmonary adenocarcinoma from metastatic tumors; positive staining for cytokeratin and thyroid transcription factor-1 (TTF-1) supports a pulmonary origin. Special stains, such as mucicarmine, can highlight mucin production.

Surgical resection is the treatment of choice for pulmonary adenocarcinoma. Lobectomy, either via thoracotomy or thoracoscopy, is recommended for solitary masses without evidence of metastasis. Complete excision with clean margins is associated with a better prognosis. For non-surgical candidates or for tumors that are not amenable to complete resection, chemotherapy may be considered. The most commonly used chemotherapeutic agents include carboplatin (dogs: 300 mg/m² IV q3-4 weeks; cats: 200-250 mg/m² IV q3-4 weeks) and doxorubicin (dogs: 30 mg/m² IV q3 weeks; cats: 1 mg/kg IV q3 weeks). Metronomic chemotherapy with cyclophosphamide (10 mg/m² PO q24h) and piroxicam (0.3 mg/kg PO q24h) has also been used. Palliative radiation therapy may be employed to relieve clinical signs in cases of non-resectable tumors. Supportive care includes management of pleural effusion via thoracocentesis or pleurodesis, oxygen therapy for hypoxemia, and nutritional support. Pain management with opioids (e.g., tramadol 2-5 mg/kg PO q8-12h) may be necessary in advanced cases.

The prognosis for pulmonary adenocarcinoma is guarded to poor, depending on the stage at diagnosis and the success of surgical resection. In dogs, the median survival time after surgical resection of a solitary lung mass is approximately 12-18 months, with a 1-year survival rate of about 50%. Factors associated with a worse prognosis include large tumor size (>5 cm), high histologic grade, presence of metastasis, and incomplete surgical margins. In cats, the prognosis is generally worse, with median survival times of 6-12 months after surgery. The presence of pleural effusion is a negative prognostic indicator. Paraneoplastic syndromes, such as hypertrophic osteopathy, may resolve after tumor removal, but their presence does not necessarily worsen the prognosis. Overall, early detection and complete surgical excision offer the best chance for prolonged survival.

After treatment, regular follow-up is essential to monitor for recurrence or metastasis. For the first year, thoracic radiographs or CT should be repeated every 2-3 months. After one year, the interval can be extended to every 4-6 months. Physical examination should be performed at each visit, with particular attention to respiratory signs and lymph node palpation. If chemotherapy is administered, CBC and serum biochemistry should be monitored before each dose to assess for myelosuppression and organ toxicity. In cases of hypertrophic osteopathy, limb radiographs may be repeated to assess resolution. Owners should be educated to monitor for signs of respiratory distress, coughing, or weight loss, and to seek veterinary attention promptly if these occur.

Pearls: 1) Always consider pulmonary adenocarcinoma in older dogs and cats with a chronic cough and a solitary pulmonary mass on radiographs. 2) Thoracic CT is essential for accurate staging and surgical planning. 3) Histopathology is required for definitive diagnosis; cytology alone may be misleading. 4) Surgical resection offers the best prognosis; refer to a veterinary surgeon early. 5) Monitor for paraneoplastic syndromes, such as hypertrophic osteopathy, which may resolve after tumor removal. Pitfalls: 1) Do not assume a pulmonary mass is metastatic without thorough staging; primary lung tumors are common. 2) Avoid fine-needle aspiration of a pulmonary mass without imaging guidance, as it may cause pneumothorax. 3) Do not delay surgery for multiple diagnostic tests; early intervention improves outcomes. 4) Be cautious with chemotherapy in cats, as they are more sensitive to myelosuppression. 5) Do not overlook the possibility of pleural effusion in cats, which may obscure the underlying mass on radiographs.

Chemotherapy protocols for pulmonary adenocarcinoma are based on extrapolation from human medicine and limited veterinary studies. Carboplatin is commonly used in dogs at a dose of 300 mg/m² IV every 3-4 weeks. In cats, the dose is 200-250 mg/m² IV every 3-4 weeks. Doxorubicin is another option: dogs receive 30 mg/m² IV every 3 weeks, while cats receive 1 mg/kg IV every 3 weeks. Metronomic chemotherapy with cyclophosphamide (10 mg/m² PO q24h) and piroxicam (0.3 mg/kg PO q24h) may be used as maintenance therapy. Piroxicam should be used with caution in cats due to the risk of renal toxicity. For pain management, tramadol (2-5 mg/kg PO q8-12h) or gabapentin (5-10 mg/kg PO q8-12h) may be used. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) can be used for pain and inflammation, but should be avoided in patients with renal or gastrointestinal disease. Antiemetics, such as maropitant (1 mg/kg IV or SC q24h), may be needed during chemotherapy. All dosages should be adjusted based on renal and hepatic function, and patients should be monitored for adverse effects.

The veterinary literature on pulmonary adenocarcinoma is limited, but several studies have provided valuable insights. A retrospective study by McNiel et al. (1997) evaluated 101 dogs with primary lung tumors and found that surgical resection resulted in a median survival time of 12 months, with tumor size and histologic grade being significant prognostic factors. Another study by Polton et al. (2008) reported that dogs with stage I disease (no lymph node involvement) had a median survival of 18 months, while those with stage II or III had shorter survival. In cats, a study by Hahn and McEntee (1997) reported a median survival of 6 months after surgical resection, with pleural effusion being a negative prognostic indicator. The use of chemotherapy in addition to surgery has not been shown to significantly improve survival in dogs, but it may be considered for high-grade tumors or incompletely excised masses. Metronomic chemotherapy has shown promise in small studies, but larger trials are needed. Overall, the evidence supports early surgical intervention as the primary treatment, with chemotherapy reserved for advanced or non-resectable disease.